printing approaches Search Results


hybrid printing approach  (BioMimetic Therapeutics)
90
BioMimetic Therapeutics hybrid printing approach
Hybrid Printing Approach, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/printing+approaches/hybrid+printing+approach/pmc07546434-46-11-27
Average 90 stars, based on 1 article reviews
hybrid printing approach - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
high-precision piezo-print microdosing approach  (Eyenovia Inc)
90
Eyenovia Inc high-precision piezo-print microdosing approach
Mean diurnal IOP at baseline (unmedicated), Day 1, and Day 2 after 0.4 µg of 0.005% µRx-latanoprost morning <t>microdosing</t> and percentage change in mean diurnal IOP on Day 1 and Day 2 from the baseline. Note: Data derived from the left/right eye average measurements for 29 evaluable subjects.
High Precision Piezo Print Microdosing Approach, supplied by Eyenovia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/printing+approaches/high+precision+piezo+print+microdosing+approach/pmc06276603-123-1-0
Average 90 stars, based on 1 article reviews
high-precision piezo-print microdosing approach - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
all-printed approach  (Verlag GmbH)
90
Verlag GmbH all-printed approach
Mean diurnal IOP at baseline (unmedicated), Day 1, and Day 2 after 0.4 µg of 0.005% µRx-latanoprost morning <t>microdosing</t> and percentage change in mean diurnal IOP on Day 1 and Day 2 from the baseline. Note: Data derived from the left/right eye average measurements for 29 evaluable subjects.
All Printed Approach, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/printing+approaches/all+printed+approach/10__1002_slash_adbi__201700136-39-13-9
Average 90 stars, based on 1 article reviews
all-printed approach - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Mean diurnal IOP at baseline (unmedicated), Day 1, and Day 2 after 0.4 µg of 0.005% µRx-latanoprost morning microdosing and percentage change in mean diurnal IOP on Day 1 and Day 2 from the baseline. Note: Data derived from the left/right eye average measurements for 29 evaluable subjects.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose

doi: 10.2147/OPTH.S185027

Figure Lengend Snippet: Mean diurnal IOP at baseline (unmedicated), Day 1, and Day 2 after 0.4 µg of 0.005% µRx-latanoprost morning microdosing and percentage change in mean diurnal IOP on Day 1 and Day 2 from the baseline. Note: Data derived from the left/right eye average measurements for 29 evaluable subjects.

Article Snippet: Eyenovia’s high-precision piezo-print microdosing approach is widely applicable for treating many front-of-the-eye diseases such as glaucoma, dry eye, allergic eye disease, and many ocular pathologies with infectious and immunologic etiologies.

Techniques: Derivative Assay

Mean diurnal IOP for average of left and right eyes after morning microdosing with 8 µL of 0.005% µRx-latanoprost (0.4 µg total dose). Note: N=29 evaluable subjects. Abbreviations: D, day; H, hour.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose

doi: 10.2147/OPTH.S185027

Figure Lengend Snippet: Mean diurnal IOP for average of left and right eyes after morning microdosing with 8 µL of 0.005% µRx-latanoprost (0.4 µg total dose). Note: N=29 evaluable subjects. Abbreviations: D, day; H, hour.

Article Snippet: Eyenovia’s high-precision piezo-print microdosing approach is widely applicable for treating many front-of-the-eye diseases such as glaucoma, dry eye, allergic eye disease, and many ocular pathologies with infectious and immunologic etiologies.

Techniques: